

# Francesco Marongiu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1089911/publications.pdf>

Version: 2024-02-01

127  
papers

3,668  
citations

201385

27  
h-index

138251

58  
g-index

127  
all docs

127  
docs citations

127  
times ranked

3406  
citing authors

#	ARTICLE	IF	CITATIONS
1	Over-anticoagulation by vitamin K antagonists and gender differences. <i>International Journal of Cardiology</i> , 2022, , .	0.8	0
2	The Repeatable Battery for the Assessment of Neuropsychological Status as a screening strategy for HIV-Associated Neurocognitive Disorders. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 357-363.	0.6	5
3	Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Societ� Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Societ� Italiana per lo Studio dell'Emostasi e della Trombosi (SISFET). <i>Journal of Nephrology</i> , 2021, 34, 31-38.	0.9	6
4	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 531-535.	1.9	40
5	Sub-muscular Reconstruction after NAC Sparing Mastectomy: Direct to Implant Breast Reconstruction with Human ADM Versus Tissue Expander. <i>Aesthetic Plastic Surgery</i> , 2021, 45, 413-420.	0.5	12
6	��Bifidus pedicle�, The Use of Bilobed Superomedial Pedicle for Breast Reshaping Following Upper Outer Quadrantectomy: A New Oncoplastic Breast Surgery Technique. <i>Aesthetic Plastic Surgery</i> , 2021, 45, 866-874.	0.5	6
7	Invited Response One: Blood Supply and Rotation of the ��Bifidus Pedicle�. <i>Aesthetic Plastic Surgery</i> , 2021, 45, 1927-1928.	0.5	0
8	Role of circulating endothelial cells in assessing the severity of systemic sclerosis and predicting its clinical worsening. <i>Scientific Reports</i> , 2021, 11, 2681.	1.6	8
9	Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk. <i>International Journal of Clinical Practice</i> , 2021, 75, e14064.	0.8	1
10	The First Use of Human-Derived ADM in Prepectoral Direct-to-Implant Breast Reconstruction after Skin-Reducing Mastectomy. <i>Aesthetic Plastic Surgery</i> , 2021, 45, 2048-2057.	0.5	1
11	Clot Characterization by Multidisciplinary Approach: Biochemical and Imaging Parameters in A Hypocoagulative Setting. A Pilot Study. <i>Journal of Public Health Research</i> , 2021, 10, jphr.2021.2358.	0.5	1
12	Invited Response on: Comment on ��The First use of Human-Derived ADM in Prepectoral Direct-to-Implant Breast Reconstruction after Skin Reducing Mastectomy.�. <i>Aesthetic Plastic Surgery</i> , 2021, 45, 1934-1935.	0.5	2
13	Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants. <i>International Journal of Cardiology</i> , 2021, 333, 162-166.	0.8	10
14	Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants. <i>International Journal of Cardiology</i> , 2021, 339, 134-137.	0.8	1
15	Invited Response on: ��Submuscular Reconstruction After NAC Sparing Mastectomy: Direct to Implant Breast Reconstruction with Human ADM Versus Tissue Expander�. <i>Aesthetic Plastic Surgery</i> , 2021, 45, 1372-1374.	0.5	0
16	Infectious agents including COVID-19 and the involvement of blood coagulation and fibrinolysis. A narrative review. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 3886-3897.	0.5	5
17	Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al.. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 136-137.	1.0	0
18	A New Human-Derived Acellular Dermal Matrix for 1-Stage Coverage of Exposed Tendons in the Foot. <i>International Journal of Lower Extremity Wounds</i> , 2020, 19, 78-85.	0.6	12

#	ARTICLE	IF	CITATIONS
19	Olanzapine-Associated Portal and Superior Mesenteric Vein Thrombosis. American Journal of Therapeutics, 2020, 27, e419-e420.	0.5	2
20	Optimizing Tailored DIEP Flap Insetting in Unilateral Immediate Free Autologous Breast Reconstruction. Plastic and Reconstructive Surgery, 2020, 145, 443e-444e.	0.7	1
21	Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. Frontiers in Immunology, 2020, 11, 605688.	2.2	92
22	Thrombosis centres and AVKs monitoring in COVID-19 pandemic. Internal and Emergency Medicine, 2020, 15, 1365-1368.	1.0	5
23	Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease?. TH Open, 2020, 04, e300-e302.	0.7	4
24	Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. European Journal of Internal Medicine, 2020, 80, 73-77.	1.0	7
25	Vaping effects on asthma: results from a web survey and clinical investigation. Internal and Emergency Medicine, 2020, 15, 663-671.	1.0	9
26	A "Catastrophic" Heparin-Induced Thrombocytopenia. Case Reports in Medicine, 2020, 2020, 1-3.	0.3	8
27	Pulmonary thrombosis in 2019-nCoV pneumonia?. Journal of Thrombosis and Haemostasis, 2020, 18, 1511-1513.	1.9	75
28	Empathy and the Educational Approach to Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants. American Journal of Therapeutics, 2020, Publish Ahead of Print, e355-e357.	0.5	0
29	Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and Siset. Blood Transfusion, 2020, 18, 478-485.	0.3	2
30	Pulmonary Thrombosis: A Clinical Pathological Entity Distinct from Pulmonary Embolism?. Seminars in Thrombosis and Hemostasis, 2019, 45, 778-783.	1.5	36
31	Optimizing DIEP Flap Insetting for Immediate Unilateral Breast Reconstruction: A Prospective Cohort Study of Patient-Reported Aesthetic Outcomes. Plastic and Reconstructive Surgery, 2019, 143, 261e-270e.	0.7	22
32	Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rFVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 235, 77-80.	0.5	13
33	A Sardinian Family with Factor XI Deficiency. Hamostaseologie, 2019, 39, 398-403.	0.9	1
34	Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis?. International Journal of Laboratory Hematology, 2019, 41, 118-123.	0.7	14
35	Direct oral anticoagulants: what can we learn?. Internal and Emergency Medicine, 2018, 13, 989-992.	1.0	3
36	Comparison of prothrombin time <sc>INR</sc> and clot waveform analysis performed with 129-µmol/L and 105-µmol/L citrate tubes. International Journal of Laboratory Hematology, 2018, 40, e15-e16.	0.7	1

#	ARTICLE	IF	CITATIONS
37	A New Human-Derived Acellular Dermal Matrix for Breast Reconstruction Available for the European Market: Preliminary Results. <i>Aesthetic Plastic Surgery</i> , 2018, 42, 434-441.	0.5	19
38	The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. <i>Internal and Emergency Medicine</i> , 2018, 13, 1029-1036.	1.0	27
39	Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No. <i>Internal and Emergency Medicine</i> , 2018, 13, 1015-1018.	1.0	2
40	Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor ( $CHA_2DS_2-VASc$ 1 or 2): A treatment dilemma. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12310.	1.1	2
41	The venous thromboembolic risk and the clot wave analysis: a useful relationship?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 448-453.	1.4	13
42	Points of Care Testing International Normalized Ratio. <i>Point of Care</i> , 2018, 17, 59-62.	0.5	0
43	Risk of reoperation in bioprosthetic valve patients with indication for long-term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study. <i>Open Heart</i> , 2018, 5, e000837.	0.9	6
44	Portable coagulometer for vitamin K-antagonist monitoring: the patients' point of view. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1521-1526.	0.8	12
45	Re. Re. Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment and review of the literature. <i>International Journal of Hematology</i> , 2018, 108, 456-457.	0.7	0
46	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. <i>Blood</i> , 2018, 132, 1365-1371.	0.6	573
47	Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena. <i>International Journal of Laboratory Hematology</i> , 2017, 39, 369-374.	0.7	14
48	Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. <i>Internal and Emergency Medicine</i> , 2017, 12, 1109-1119.	1.0	30
49	Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. <i>International Journal of Hematology</i> , 2017, 105, 532-535.	0.7	7
50	Point-of-care testing INR: an overview. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 800-805.	1.4	35
51	A Rare Case of Mondor Syndrome after Breast Reduction Surgery. Insert it into the Consent Form. <i>Breast Journal</i> , 2016, 22, 249-251.	0.4	0
52	Contralateral DIEV as an interpositional vein graft for venous supercharge in the salvage of a congested DIEP flap. <i>Microsurgery</i> , 2016, 36, 263-264.	0.6	8
53	Contralateral breast symmetrisation in unilateral DIEP flap breast reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2016, 69, 1363-1373.	0.5	19
54	A retrospective cohort study of patients with pulmonary embolism: the impact of comorbidities on patient's outcome. <i>European Respiratory Journal</i> , 2016, 48, 555-557.	3.1	15

#	ARTICLE	IF	CITATIONS
55	The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. PLoS ONE, 2015, 10, e0124719.	1.1	50
56	Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation. PLoS ONE, 2015, 10, e0144314.	1.1	16
57	Vitamin K Antagonists (Coumarins), Drugs Used in the Prevention and Treatment of Cardioembolism, Deep Vein Thrombosis, and Pulmonary Embolism. , 2015, , 395-398.		3
58	The criteria of the Italian Federation of Thrombosis Centres on DOACs: a "real world" application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist. Internal and Emergency Medicine, 2015, 10, 157-163.	1.0	12
59	Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency. Thrombosis and Haemostasis, 2014, 112, 1182-1189.	1.8	17
60	Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills. Internal and Emergency Medicine, 2014, 9, 897-898.	1.0	2
61	Thromboembolic disease in patients with rheumatoid arthritis undergoing joint arthroplasty: Update on prophylaxes. World Journal of Orthopedics, 2014, 5, 645.	0.8	4
62	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2013, 11, 1205-1206.	1.9	1
63	Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home. Journal of Telemedicine and Telecare, 2013, 19, 298-301.	1.4	16
64	Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. Journal of Thrombosis and Haemostasis, 2012, 10, 1979-1987.	1.9	29
65	Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists. Thrombosis Research, 2012, 129, e168-e170.	0.8	11
66	Management of special conditions in patients on vitamin K antagonists. Internal and Emergency Medicine, 2012, 7, 407-413.	1.0	1
67	Special indications for vitamin K antagonists: a review. Internal and Emergency Medicine, 2012, 7, 21-25.	1.0	5
68	Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation.. Thrombosis and Haemostasis, 2011, 106, 868-876.	1.8	158
69	Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood, 2011, 118, 4714-4718.	0.6	404
70	A routine silica-based activated partial thromboplastin time (Hemosil aPTT <sup>ASP</sup> ) mostly excludes the presence of lupus anticoagulant. International Journal of Laboratory Hematology, 2011, 33, e12-3.	0.7	1
71	Thyroid Disorders and Hypocoagulability. Seminars in Thrombosis and Hemostasis, 2011, 37, 011-016.	1.5	10
72	High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice. Clinical Chemistry and Laboratory Medicine, 2011, 49, 695-698.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. <i>Blood</i> , 2010, 115, 481-488.	0.6	134
74	Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190BCRâ€“ABL oncoprotein and JAK2V617F mutation. <i>Leukemia Research</i> , 2010, 34, e27-e29.	0.4	11
75	Clinical course of highâ€risk patients diagnosed with antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 237-242.	1.9	527
76	Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). <i>Thrombosis Research</i> , 2010, 126, 150-153.	0.8	30
77	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , 2009, 84, 579-583.	2.0	28
78	Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful?. <i>Thrombosis Research</i> , 2009, 123, 775-779.	0.8	22
79	Rheumatoid arthritis and thrombosis. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, 846-55.	0.4	17
80	Hemarthrosis as acute presentation of acquired hemophilia in a patient with systemic lupus erythematosus: successful treatment and long-lasting remission. <i>Clinical Rheumatology</i> , 2008, 27, 1581-1584.	1.0	9
81	A Comparison of Lupus Anticoagulantâ€Positive Patients With Clinical Picture of Antiphospholipid Syndrome and Those Without. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, e309-10.	1.1	43
82	Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 925-930.	1.9	95
83	A â€two-stepâ€educational approach for patients taking oral anticoagulants does not improve therapy control. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 185-190.	1.0	12
84	Oral anticoagulant therapy and telemedicine. <i>Internal and Emergency Medicine</i> , 2006, 1, 166-167.	1.0	2
85	The future of anticoagulation clinics: a journey to thrombosis centers?. <i>Haematologica</i> , 2005, 90, 298.	1.7	9
86	Thyroid, hemostasis and thrombosis. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 1065-1071.	1.8	42
87	Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2003, 32, 285-295.	1.6	133
88	Oral anticoagulant therapy: should doctors change the way they give patients explanations ?. <i>Thrombosis and Haemostasis</i> , 2003, 90, 159-160.	1.8	3
89	Oral anticoagulant therapy: should doctors change the way they give patients explanations?. <i>Thrombosis and Haemostasis</i> , 2003, 90, 159-60.	1.8	1
90	Apathetic Gravesâ€™ disease and acquired hemophilia due to factor VIIIc antibody. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 246-249.	1.8	11

#	ARTICLE	IF	CITATIONS
91	Patient education and oral anticoagulant therapy. Haematologica, 2002, 87, 1081-6.	1.7	52
92	The Management of Oral Anticoagulant Therapy: The Patient's Point of View. Thrombosis and Haemostasis, 2000, 83, 49-53.	1.8	50
93	Dermatan Sulphate, Heparin Cofactor II, and F1+2 Peptide in Non-Insulin-Dependent Diabetes Mellitus. Thrombosis Research, 2000, 97, 263-265.	0.8	3
94	The management of oral anticoagulant therapy: the patient's point of view. Thrombosis and Haemostasis, 2000, 83, 49-53.	1.8	18
95	Warfarin or Acenocoumarol: Which Is better in the Management of Oral Anticoagulants?. Thrombosis and Haemostasis, 1998, 80, 899-902.	1.8	65
96	Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?. Thrombosis and Haemostasis, 1998, 80, 899-902.	1.8	22
97	Inhibition of blood coagulation activation and oral anticoagulants in patients with mechanical heart valve prostheses. Thrombosis Research, 1996, 81, 403-406.	0.8	3
98	THE OLD MANUAL TILT TUBE THROMBOTEST: STILL USEFUL IN THE MANAGEMENT OF ORAL ANTICOAGULANTS?. Thrombosis Research, 1996, 84, 379-384.	0.8	0
99	Comparison between Recombinant and Rabbit Thromboplastin in the Management of Patients on Oral Anticoagulant Therapy. Thrombosis and Haemostasis, 1996, 75, 488-490.	1.8	7
100	Uneven hepatic iron and phosphorus distribution in beta-thalassemia. Journal of Hepatology, 1995, 23, 544-549.	1.8	91
101	Prothrombin Fragment F 1+2 Levels are High in NIDDM Patients Independently of the Hb A1 c. Thrombosis and Haemostasis, 1995, 74, 805-806.	1.8	6
102	Abnormalities of Blood Coagulation and Fibrinolysis in Psoriasis. Dermatology, 1994, 189, 32-37.	0.9	34
103	Bleeding Time and Oral Anticoagulant Therapy. Thrombosis and Haemostasis, 1993, 69, 523-524.	1.8	0
104	Known vitamin K intake and management of poorly controlled oral anticoagulant therapy. Lancet, The, 1992, 340, 545-546.	6.3	11
105	Is a Hypercoagulable State Present in Hypothyroidism?. Thrombosis and Haemostasis, 1992, 67, 729-729.	1.8	18
106	Anticardiolipin antibodies in Grave's disease: Relationship with thrombin activity in vivo. Thrombosis Research, 1991, 64, 745-749.	0.8	43
107	Activation of Blood Coagulation and Fibrinolysis in Graves' Disease. Hormone and Metabolic Research, 1991, 23, 609-611.	0.7	28
108	The Behaviour of Protein C in Diabetes Is still an Open Question. Thrombosis and Haemostasis, 1991, 66, 267-267.	1.8	4

#	ARTICLE	IF	CITATIONS
109	Thrombin Activity and Oral Anticoagulant Therapy: A Further Evaluation. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1990, 20, 63-64.	0.5	3
110	Changes in fibrinolysis in patients with localized tumors. European Journal of Cancer & Clinical Oncology, 1990, 26, 83-87.	0.9	11
111	Bleeding time is prolonged during oral anticoagulant therapy. Thrombosis Research, 1990, 59, 905-912.	0.8	5
112	t-PA Activity elicited by venous occlusion or DDAVP infusion does not produce plasmin activity in normal subjects. Thrombosis Research, 1990, 59, 1007-1011.	0.8	1
113	Is the imbalance between thrombin and plasmin activity in diabetes related to the behaviour of antiplasmin activity?. Thrombosis Research, 1990, 58, 91-99.	0.8	19
114	Evidence for a Relationship between High Fibrinogen Levels and Decreased Thrombin Activity in vivo in Elderly Subjects. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1989, 19, 91-93.	0.5	1
115	Thrombin Activity and Oral Anticoagulant Therapy: A Preliminary Study. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1989, 19, 142-146.	0.5	4
116	T lymphocyte subsets and viral infections in sardinian parenteral drug abusers: Relationship to HIV infection. Journal of Medical Virology, 1989, 27, 81-86.	2.5	5
117	Fibrin(ogen) Peptides in Early Breast Cancer. Thrombosis and Haemostasis, 1989, 62, 819.	1.8	2
118	Acute and chronic hepatitis delta virus infection: Direct or indirect effect on hepatitis B virus replication?. Journal of Medical Virology, 1988, 26, 279-288.	2.5	22
119	Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment. Journal of Endocrinological Investigation, 1988, 11, 723-725.	1.8	36
120	Fibrinopeptide A and B $\beta$ 15-42 in Liver Cirrhosis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1988, 18, 126-128.	0.5	0
121	Thrombocytopenia and liver cirrhosis evidence for relationship between platelet count, spleen size and hepatic synthetic activity. Thrombosis Research, 1987, 45, 275-278.	0.8	8
122	FIBRINOPEPTIDE BB 15-42 AND FIBRINOPEPTIDE A IN ATHEROSCLEROTIC DISEASE. Thrombosis and Haemostasis, 1987, 58, 2035.	1.8	0
123	FIBRINOPEPTIDE B6 15-42 IN LIVER CIRRHOSIS: A SENSITIVE INDICATOR OF MILD FIBRINOLYSIS ACTIVATION. , 1987, 58, 0264.		0
124	Relationship between Elevated Fibrinopeptide A Levels and Alpha-2-Antiplasmin. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1987, 17, 301-304.	0.5	0
125	$\hat{\pm}$ 2antiplasmin and disseminated intravascular coagulation in liver cirrhosis. Thrombosis Research, 1985, 37, 287-294.	0.8	32
126	Acute Erythroblastic Leukemia Terminating a Very Long-Lasting (27 Years) Hodgkin's Disease. Acta Haematologica, 1982, 67, 287-288.	0.7	1



#	ARTICLE	IF	CITATIONS
127	Chronic spontaneous urticaria: a low-grade disseminated intravascular coagulation only partially reversed by Omalizumab. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	0